New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2014
08:00 EDTBSXBoston Scientific upgraded at Oppenheimer
As previously reported, Oppenheimer upgraded Boston Scientific to Overweight from Equal Weight. The firm upgraded shares to reflect pipeline acceleration and margin improvement in cardiology. Price target is $15.
News For BSX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 1, 2015
13:40 EDTBSXBoston Scientific suspends share buyback for next 12-18 months
Subscribe for More Information
13:34 EDTBSXBoston Scientific sees new devices expanding profit margins, Bloomberg says
Boston Scientific sees cost cutting plans and manufacturing new devices more efficiently as helping the company to boost operating profits beyond the 25% goal set for 2017, says Bloomberg. Reference Link
07:58 EDTBSXBoston Scientific sees FY17-FY19 adjusted EPS to see double digit growth
Sees FY17-FY10 operational revenue to see upside from potential M&A. Sees FY17 organic revenue growth up 3%-5% and FY17 adjusted operation margin up 25%. Sees FY18-FY19 operational revenue growth up 3%-7% and FY18-FY19 adjusted operation margin 50-100 bps annually.
07:56 EDTBSXBoston Scientific sees FY16 double digit growth in adjusted EPS, consensus $1.02
Subscribe for More Information
07:55 EDTBSXBoston Scientific backs FY15 adjusted EPS 88c-92c, consensus 90c
Subscribe for More Information
April 30, 2015
08:49 EDTBSXBoston Scientific collaborates with MedAxiom and TogetherMD
Subscribe for More Information
April 28, 2015
11:52 EDTBSXBoston Scientific to pay $119M to resolve 2,970 product liability claims
Subscribe for More Information
11:25 EDTBSXBoston Scientific to host investor day
Subscribe for More Information
07:05 EDTBSXBoston Scientific sees Q2 adjusted EPS 20c-22c, consensus 22c
Subscribe for More Information
07:05 EDTBSXBoston Scientific backs FY15 adjusted EPS 88c-92c, consensus 91c
Cuts FY15 revenue to $7.23B-$7.38B from $7.3B-$7.5B, consensus $7.43B.
07:04 EDTBSXBoston Scientific reports Q1 Cardiovascular revenue up 10% to $712M
Reports Q1 Rhythm Management revenue up 4% to $514M; Reports Q1 MedSurg revenue up 4% to $542M.
07:02 EDTBSXBoston Scientific reports Q1 adjusted EPS 21c, consensus 21c
Reports Q1 revenue $1.77B, consensus $1.78B
05:51 EDTBSXBoston Scientific drug Eluvia trial meets primary endpoint
Subscribe for More Information
April 27, 2015
16:23 EDTBSXBoston Scientific announces strategic collaboration with Brainlab AG
Subscribe for More Information
15:04 EDTBSXNotable companies reporting before tomorrow's open
Subscribe for More Information
April 20, 2015
16:09 EDTBSXBoston Scientific announces long-term data underscore safety, efficacy of S-ICD
The Journal of the American College of Cardiology published data confirming the long-term safety and efficacy of the Boston Scientific S-ICD System for patients at risk of sudden cardiac arrest. The study, "Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator: 2-year Results from a Pooled Analysis of the IDE Study and EFFORTLESS Registry" was led by Dr. Martin Burke, professor of medicine at the University of Chicago. The analysis combined data from two large S-ICD studies to provide the most comprehensive look at S-ICD System patient outcomes to date. The all-cause mortality rate for the S-ICD patients was 1.6% per year, comparing favorably to observed mortality rates in similar TV-ICD studies. Currently, the S-ICD System is covered nationally by Medicare, Aetna, Cigna and others, and regionally by numerous private and Medicaid plans, providing coverage for approximately 170M individuals in the U.S. The S-ICD System has been commercially available in Europe since 2009.
07:44 EDTBSXSurvey shows strong momentum for Boston Scientific devices, says RBC Capital
RBC Capital says that its survey supports strong momentum for Boston Scientific's S-ICD and Watchman, and the firm thinks the company is probably gaining share in single-chamber ICDs. The firm raised its price target on the shares to $20 from $17 and recommends buying the shares at current levels or on pullbacks.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use